A Randomised, Double-blind, Parallel Group PhIII Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps - SYNAPSE (StudY in NAsal Polyps Patients to Assess the Safety and Efficacy of Mepolizumab)
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2018
At a glance
- Drugs Mepolizumab (Primary) ; Mometasone
- Indications Nasal polyps
- Focus Registrational; Therapeutic Use
- Acronyms SYNAPSE
- Sponsors GlaxoSmithKline Research & Development
- 03 May 2018 Planned End Date changed from 2 Aug 2019 to 26 Dec 2019.
- 03 May 2018 Planned primary completion date changed from 2 Aug 2019 to 26 Dec 2019.
- 18 Jan 2018 Planned End Date changed from 20 Jun 2019 to 2 Aug 2019.